115,380 Shares in Concentrix Corporation $CNXC Acquired by Ieq Capital LLC

Ieq Capital LLC acquired a new position in Concentrix Corporation (NASDAQ:CNXC) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 115,380 shares of the company’s stock, valued at approximately $2,585,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CNXC. Royal Bank of Canada lifted its holdings in Concentrix by 9.5% in the 1st quarter. Royal Bank of Canada now owns 47,501 shares of the company’s stock worth $2,643,000 after buying an additional 4,133 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Concentrix by 75.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 423,287 shares of the company’s stock valued at $23,552,000 after purchasing an additional 181,546 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Concentrix by 17.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 146,515 shares of the company’s stock valued at $8,152,000 after buying an additional 21,746 shares during the last quarter. Focus Partners Wealth purchased a new position in shares of Concentrix during the 1st quarter valued at approximately $781,000. Finally, Geneos Wealth Management Inc. grew its position in shares of Concentrix by 532.7% during the first quarter. Geneos Wealth Management Inc. now owns 620 shares of the company’s stock worth $34,000 after buying an additional 522 shares in the last quarter. 90.34% of the stock is owned by institutional investors and hedge funds.

Concentrix Price Performance

CNXC opened at $26.03 on Tuesday. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -1.22, a price-to-earnings-growth ratio of 0.47 and a beta of 0.45. Concentrix Corporation has a fifty-two week low of $19.12 and a fifty-two week high of $57.88. The company’s 50-day moving average price is $24.42 and its 200 day moving average price is $27.37. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 1.46.

Concentrix (NASDAQ:CNXC) last issued its earnings results on Monday, June 29th. The company reported $2.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.01). Concentrix had a positive return on equity of 19.82% and a negative net margin of 13.16%.The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.47 billion. During the same period in the prior year, the business earned $2.70 EPS. The business’s revenue was up 1.9% on a year-over-year basis. Concentrix has set its FY 2026 guidance at 10.830-11.180 EPS and its Q3 2026 guidance at 2.650-2.770 EPS. As a group, sell-side analysts expect that Concentrix Corporation will post 9.67 earnings per share for the current year.

Concentrix Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 4th. Investors of record on Friday, July 24th were issued a $0.36 dividend. The ex-dividend date of this dividend was Friday, July 24th. This represents a $1.44 annualized dividend and a dividend yield of 5.5%. Concentrix’s dividend payout ratio (DPR) is -6.75%.

Wall Street Analyst Weigh In

CNXC has been the topic of several recent analyst reports. Zacks Research cut shares of Concentrix from a “hold” rating to a “strong sell” rating in a report on Thursday, July 2nd. Bank of America cut their price objective on Concentrix from $32.00 to $26.00 and set a “neutral” rating on the stock in a research note on Tuesday, June 30th. Canaccord Genuity Group reduced their target price on Concentrix from $55.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Weiss Ratings reiterated a “sell (d)” rating on shares of Concentrix in a research report on Friday, July 24th. Finally, Robert W. Baird reduced their price objective on Concentrix from $40.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 30th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $32.75.

Concentrix Profile

Concentrix Inc (NASDAQ: CNXC) is a global business services company specializing in customer engagement solutions and technology‐driven business process outsourcing. The firm’s offerings encompass customer care delivered across voice and digital channels, back‐office processing, analytics and consulting, and automated workflow management. By integrating proprietary platforms, strategic partnerships and advanced automation, Concentrix helps clients enhance customer experiences and streamline operations.

Its capabilities extend to digital marketing and technology implementation, leveraging artificial intelligence, machine learning and data analytics to optimize customer journeys.